Repatha Injection Sites
Repatha (evolocumab) should be injected subcutaneously into the abdomen, thigh, or upper arm. 1
Approved Injection Sites
According to the FDA-approved prescribing information, Repatha can be administered in three specific anatomical locations 1:
- Abdomen (avoiding the area around the navel)
- Thigh (anterior/lateral aspect)
- Upper arm (posterior aspect)
Important Administration Guidelines
Site rotation is mandatory - you must rotate injection sites with each administration to prevent lipohypertrophy and ensure consistent drug absorption 1. Avoid injecting into areas that are:
- Tender or bruised
- Red or indurated
- Scarred or have stretch marks
Practical Considerations
The 2022 ACC Expert Consensus specifically confirms these same three sites (thigh, abdomen, upper arm) for both alirocumab and evolocumab PCSK9 inhibitors 2. Research data supports that pharmacokinetics and pharmacodynamics are similar across all three injection sites, meaning the drug works equally well regardless of which approved site you choose 3.
For the 420 mg dose, you have two options 1:
- Use the single-dose on-body infusor (administered over 5 minutes)
- Give 3 consecutive injections of 140 mg within 30 minutes using different injection sites
Key Safety Note
Latex sensitivity matters - some Repatha presentations contain dry natural rubber (latex derivative) in the needle cover 1. If your patient is latex-sensitive, specifically request a latex-free presentation from the pharmacy.
The drug must be warmed to room temperature before injection: 30 minutes for prefilled syringes/autoinjectors, or 45 minutes for the on-body infusor 1.